EphemerisX Research · Deep research
Cross-investigations whose records belong together as a regulatory pathway. How this research works →
AllComparable evidenceDivergent outcomeRegulatory pathwayShared concern
These records describe the classes only by review time: six months for Class 2, 60 days for Class 1. Replimune and Outlook each moved from a Class 2 review to a Class 1 resubmission; CorMedix and Aldeyra resubmissions were reviewed as Class 2.
Aldeyra Therapeutics · CorMedix · Outlook Therapeutics · ReplimuneRead →
Prepared from public FDA letters and SEC filings: every quoted passage is matched to the original document, and every “not in” statement comes from a search of the whole document, before it is published. Questions, summaries and connecting sentences are EphemerisX’s wording. Not investment advice. How this research works → · Ask the FDA and SEC Ephemeris →
